Signalisation PI3K/Akt/mTOR

Petosemtamab (MCLA 158), a dual-action monoclonal antibody targets EGFR & LGR5, used in solid tumor research like HNSCC & CRC.

Rociletinib (CNX-419) is an orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic

Lapatinib ditosylate monohydrate: a drug for advanced breast cancer; may cause liver issues.

Parsaclisib (INCB050465) is a potent and selective inhibitor of PI3Kδ(IC50 of 1 nM at 1 mM ATP)

BLU-945 is a reversible, potent, highly selective, and orally available epidermal growth factor receptor tyrosine kinase inhibitor (TKIs).Cost-effective and quality-assured.

FRATtide inhibits the phosphorylation of Axin and β-catenin, inhibits GSK-3 binding to Axin, and is a peptide derived from the GSK-3 binding protein.

Multi-target kinase inhibitor 4 (Compound 2) is a PI3K/DNA-PK inhibitor and a potent chemosensitizer that enhances the number of DNA double-strand breaks induced by Doxorubicin. It serves as an effective multidrug resistance (MDR) inhibitor, demonstrating inhibitory activity against P-glycoprotein (P-gp) mediated drug efflux. Multi-target kinase inhibitor 4 can be encapsulated in PEG-coated lipid nanoparticles.

A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.